Tablets and ampoules
Each dosage unit contains :
Orphenadrine Citrate BP : Tablet 100mg AND Ampoule (2ml) 60mg
Norflex (orphenadrine citrata ) gives rapid relief from painful conditions of the Norflex musculo skeletal system It acts centrally by blocking reticular facilitation Le. it blocks preferentially those
pathways whose hyperactivity leads to an exaggeration of motor function such as spasticity, rigidity or muscle spasm.
Norflex Is indicated for the short term symptomatic relief of painful conditions of the musculo-skeletal system such as low back pain and lumbago.
Dosage and Administration :
Tablets Adults : 2 tablets daily, 1 in the morning and 1 in the evening.
Injection Adults : The contents of one 2 rnl ( 60 mg ) ampoule intramuscularty or intravenously The intravenous injection should be administered over a period of about five minutes, preferably with the patient lying down After the initial injection, treatment may be continued with Norflex tablets ( 100 mg ), one tablet twice daily, Alternatively, Norgesic tablets ( orphenadrine carate 35 mg combined with paracetamol 450 mg ) may be given in a dosage of two tablets three times a day.
Elderly: The cautions and contraindications apply particularty to elderty patients since orphenadrine, in common with other drugs with anticholinergic effects, may cause confusion ( delirium) in the
elderly, a daily dose of not more than 100 mg is recommended in patients over the age of 65.
Children : Not recommended for children under 12 years.
Side effects, warnings etc :
Side effects : Dry mouth, nausea, blurring of vision, dizziness, confusion and tremor may occur in some patients susceptible to the parasympatholytic action of orphenadrine. These symptoms rapidly
disappear following reduction of dosage or cessation of treatment. Some patients may experience a transient feeling of lightheadedness or dizziness following an injection of Norflex.
Norflex should be used with caution in patients with tachycardia.
Contra-indications to Norflex result from the parasympatholytic action of orphenadrine. Norflex should not be given to patients with glaucoma, urinary retention ( e.g. due to prostatic hypertrophy or
obstruction of the bladder neck) and myasethaenia gravis It should not be given to lactating mothers.
Symptoms of orphenadrine citrate overdosa:ge Excitement, confusion and delirium leading to coma. convulsions, tachcardia Dilated pupils and urinary retention may occur.
Treatment : Convulsions and delirium respond to relatively large doses of diaze am, preferably by mouth Adequate hydration of the patient is imf?Ortant.
There is no evidence as to drug safety in human pregnancy nor is there evidence from animal work that it is free from hazard Avoid in pregnancy unless there is no safer treatment.
Norflex tablets : blister of 10 tablets each box of 20 tablets Norflex ampoules : doxes of 3 ampoules x 2 ml
MANUFACTURED BY :
EGYPTIAN INT. PHARMACEUTICAL INDUSTRIES CO.
TENTH OF RAMADAN CITY A. R. E.
UNDER LICENCE FROM 3M HEALTH CARE· ENGLAND